Director Resignation
Director Resignation

Sydney, June 4, 2020 AEST (ABN Newswire) - Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that non-executive director Dr Glen Richards has resigned to allow him to focus on his other commitments.

Dr Richards joined the board of Regeneus as non-executive director in April 2015.

Regeneus' Independent Chairman Barry Sechos, thanked Dr Richards for his contribution.

"The Board would like to thank Glen for his tremendous efforts and deep business knowledge during his tenure as a Director. He has been an asset to Regeneus and we wish him all the best," said Mr Sechos.


About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.

      


Contact

Investors
Sandra McIntosh
Company Secretary and Investor Relations
Regeneus Ltd
T: +61-2-9499-8010
E: investors@regeneus.com.au

Media
Daniel Paperny
Media and Capital Partners
T: +61-405-191-257
E: Daniel.paperny@mcpartners.com.au



Related Companies

Regeneus Ltd      

ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 9) (Last 30 Days: 29) (Since Published: 3005)